Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 4, 2014, Pages 757-763

  Carlsson, Göran ^a   Odin, Elisabeth ^a   Gustavsson, Bengt ^a   Wettergren, Yvonne ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

5 FU; Colorectal cancer; Dihydropyrimidine dehydrogenase; Dihydrouracil; Saliva; Uracil

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DIHYDROPYRIMIDINE DEHYDROGENASE; DIHYDROURACIL; FLUOROURACIL; URACIL;

ADJUVANT CHEMOTHERAPY; AGED; ANALOGS AND DERIVATIVES; CANCER STAGING; COLORECTAL NEOPLASMS; DOSE RESPONSE; DRUG SCREENING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY; RISK ASSESSMENT; SALIVA; SEX DIFFERENCE;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SALIVA; SEX FACTORS; URACIL;

EID: 84925545990     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2553-2     Document Type: Article

References (27)

1. Carlsson G, Graf W, Gustavsson BG, Glimelius B, Pahlman L, Spears PC (1990) Sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic gastrointestinal cancer. Eur J Cancer 26:874-876
2. Sorbye H, Dahl O (2003) Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. Acta Oncol 42:827-831
3. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203-2206
4. Jiang H, Lu J, Jiang J, Hu P (2004) Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics. J Clin Pharmacol 44:1260-1272
5. Diaz R, Segura A, Aparicio J, Calderero V, Guerrero A, Pellin L (2004) Lethal toxicity after 5-fluorouracil chemotherapy and its possible relationship to dihydropyrimidine dehydrogenase deficiency: a case report and review of the literature. J Chemother 16:599-603
6. van Kuilenburg AB, Meinsma R, van Gennip AH (2004) Pyrimidine degradation defects and severe 5-fluorouracil toxicity. Nucleosides Nucleotides Nucl Acids 23:1371-1375
7. Wettergren Y, Carlsson G, Odin E, Gustavsson B (2012) Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. Cancer 118:2935-2943
8. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS et al (2000) Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:979-994
9. Lucas AS, O'Neil BH, Goldberg RM (2011) A decade of advances in cytotoxic chemotherapy for metastatic colorectal cancer. Clin Color Cancer 10:238-244
10. Hoff PM, Saad ED, Costa F, Coutinho AK, Caponero R, Prolla G, Gansl RC (2012) Literature review and practical aspects on the management of oxaliplatin-associated toxicity. Clin Color Cancer 11:93-100
11. JMP (2012) version 10.0.0. SAS Institute Inc
12. Boisdron-Celle M (2012) Pharmacokinetic adaptation of 5-fluorouracil: where are we and where are we going? Pharmacogenomics 13:1437-1439
13. Lee W, Lockhart AC, Kim RB, Rothenberg ML (2005) Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 10:104-111
14. Nagasubramanian R, Innocenti F, Ratain MJ (2003) Pharmacogenetics in cancer treatment. Annu Rev Med 54:437-452
15. Cunha-Junior GF, De Marco L, Bastos-Rodrigues L, Borges Bolina M, Linhares Martins F, Pianetti GA, Cesar IC, Coelho LG (2013) 13C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients. Cancer Chemother Pharmacol 72:1273-1282
16. Mattison LK, Fourie J, Hirao Y, Koga T, Desmond RA, King JR, Shimizu T, Diasio RB (2006) The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C] dihydrouracil. Clin Cancer Res 12:549-555
17. Gamelin E, Boisdron-Celle M, Guerin-Meyer V, Delva R, Lortholary A, Genevieve F, Larra F, Ifrah N, Robert J (1999) Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 17:1105-1110
18. Kristensen MH, Pedersen P, Mejer J (2010) The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients. J Int Med Res 38:1313-1323
19. Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L et al (2007) 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 249:271-282
20. Magné N, Etienne-Grimaldi MC, Cals L, Renee N, Formento JL, Francoual M, Milano G (2007) Dihydropyrimidine dehydrogenase activity and the IVS14 + 1G > A mutation in patients developing 5FU-related toxicity. Br J Clin Pharmacol 64:237-240
21. Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renée N (1999) Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79:627-630
22. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ (1995) Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 75:11-17
23. Chansky K, Benedetti J, Macdonald JS (2005) Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 103:1165-1171
24. Kaminski A, Joseph D, Elsaleh H (2007) Differences in toxicity across gender in patients treated with chemoradiation for rectal cancer. Australas Radiol 51:283-288
25. Milano G, Etienne MC, Cassuto-Viguier E, Thyss A, Santini J et al (1992) Influence of sex and age on fluorouracil clearance. J Clin Oncol 10:1171-1175
26. Ramani VS, Gollins SW, Wong H (2006) Weekly fluorouracil at 425 mg/m(2) plus low-dose folinic acid for 24 weeks as adjuvant treatment for colorectal cancer: assessment of toxicity and delivery. Clin Oncol (R Coll Radiol) 18:649-657
27. Hayashi K, Kidouchi K, Sumi S, Mizokami M, Orito E et al (1996) Possible prediction of adverse reactions to pyrimidine chemotherapy from urinary pyrimidine levels and a case of asymptomatic adult dihydropyrimidinuria. Clin Cancer Res 2:1937-1941